Gliptagreat 50 Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the incretin system. This mechanism increases insulin secretion from pancreatic beta cells and decreases glucagon release from alpha cells in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Gliptagreat 50 is indicated as monotherapy or in combination with other antidiabetic agents such as metformin or insulin when diet and exercise alone do not provide adequate glycemic control. It is particularly beneficial for patients who require improved postprandial glucose regulation. The medication is generally well tolerated, with a low risk of weight gain and hypoglycemia. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. It is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Renal function should be monitored periodically, and dosage adjustments may be necessary in patients with renal impairment. Gliptagreat 50 should be used under medical supervision as part of a comprehensive diabetes management plan including lifestyle modifications.